A Phase 3 Study of Enarodustat (JTZ-951) in Japanese Hemodialysis Patients for Treatment of Anemia in Chronic Kidney Disease: SYMPHONY HD Study

• Príomhchruthaitheoirí: Tadao Akizawa (Údar), Masaomi Nangaku (Údar), Takuhiro Yamaguchi (Údar), Ryosuke Koretomo (Údar), Kazuo Maeda (Údar), Yuya Miyazawa (Údar), Hideki Hirakata (Údar)
• Formáid: LEABHAR
• Foilsithe / Cruthaithe: Karger Publishers, 2021-07-01T00:00:00Z.
• Ábhair: article
• Rochtain ar líne: Connect to this object online.

Introduction: Enarodustat (JTZ-951) is a new oral hypoxia-inducible factor-prolyl hydroxylase inhibitor for the treatment of anemia in chronic kidney disease (CKD). We conducted a phase 3 study to compare the efficacy and safety of enarodustat with darbepoetin alfa (DA) in Japanese anemic patients w...